CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
Azacitidine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04146038
NCT04146038Phase 2Completed
CompareCT.gov

Salsalate + Venetoclax/Decitabine for Patients With Acute Myelogenous Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Rutgers, The State University of New Jersey·interventional·Posted Oct 31, 2019·Updated May 24, 2023

In Brief

A Phase 2 clinical trial evaluating Azacitidine, Decitabine, and 2 other interventions for Acute Myeloid Leukemia and 7 related conditions. Completed, enrolled 5 participants across 1 site.

Detailed Summary

This phase II trial studies the side effects of salsalate when added to venetoclax and decitabine or azacitidine in treating patients with acute myeloid leukemia or myelodysplasia/myeloproliferative disease that has spread to other places in the body (advanced). Drugs used in chemotherapy, such as salsalate, venetoclax, decitabine, and azacitidine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedOct 31, 2019
Enrollment StartOct 26, 2020
Primary CompletionOct 25, 2021
Study CompletionOct 25, 2022
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 6.7 years ago

Interventions

Azacitidinedrug

Given IV

Decitabinedrug

Given IV

Salsalatedrug

Given PO

Venetoclaxdrug

Given PO